| ￥3600 | |
| Z02746-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity |
> 97% as analyzed by SDS-PAGE > 97% as analyzed by HPLC |
|
| Endotoxin Level | < 1 EU/μg of protein by LAL method | |
| Expression System | E. coli | |
| Theoretical Molecular Weight | 3.5 kDa | |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. | |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. | |
| Storage & Stability | Upon receiving, this product remains stable for 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for 1 week at 4°C or for 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
»
»
| Target Background | Natriuretic Peptide Precursor B acts as a cardiac hormone with a variety of biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. It is thought to play a key role in cardiovascular homeostasis. Helps restore the body's salt and water balance. Improves heart function. |
| Synonyms | Brain natriuretic peptide; Brain natriuretic peptide 32; BNP(1-32); BNP-32 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
